Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics and keeping the price target at $18.00.

Justin Walsh has given his Buy rating due to a combination of factors that, in his view, the market is not fully recognizing. He sees the current share price weakness as a misalignment with the company’s advancing clinical pipeline, particularly the Pb-212-VMT-α-NET program, which is delivering increasingly robust responses while maintaining a cleaner safety profile relative to a key competing asset. Although the measured response rate currently trails that competitor, Walsh notes that the program remains in dose escalation, with additional patients and longer follow-up expected to better capture the full therapeutic effect. He also points to the company’s solid cash position as support for ongoing development and execution against its clinical milestones.
Walsh further emphasizes that Perspective’s strategic investments in radiopharmaceutical manufacturing are poised to create value beyond supporting its own trials. These facilities could generate excess production capacity that may be monetized through partnerships or supply agreements, while simultaneously enhancing the company’s appeal as an acquisition target in a sector where manufacturing capabilities are often central to M&A. Upcoming readouts for Pb-212-VMT01 in melanoma and Pb-212-PSV359 in solid tumors, expected around mid- to late-2026, provide additional potential catalysts that could highlight the breadth of the platform. Taken together, these clinical, manufacturing, and strategic elements underpin his Buy recommendation and $18 price target.

In another report released today, Wedbush also maintained a Buy rating on the stock with a $11.00 price target.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CATX in relation to earlier this year.